Cargando…

Defining the Optimal Method for Measuring Metabolic Tumor Volume on Preoperative (18)F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography as a Prognostic Predictor in Patients With Pancreatic Ductal Adenocarcinoma

OBJECTIVES: Metabolic tumor volume (MTV) on (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) is a promising prognostic predictor in pancreatic ductal adenocarcinoma (PDAC). However, the optimal segmentation method and threshold value to determine MTV for PDAC ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Tatewaki, Yasuko, Terao, Chiaki Maeda, Ariake, Kyohei, Saito, Ryoko, Mutoh, Tatsushi, Shimomura, Hideo, Motoi, Fuyuhiko, Mizuma, Masamichi, Odagiri, Hayato, Unno, Michiaki, Taki, Yasuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994512/
https://www.ncbi.nlm.nih.gov/pubmed/33777807
http://dx.doi.org/10.3389/fonc.2021.646141
_version_ 1783669766621233152
author Tatewaki, Yasuko
Terao, Chiaki Maeda
Ariake, Kyohei
Saito, Ryoko
Mutoh, Tatsushi
Shimomura, Hideo
Motoi, Fuyuhiko
Mizuma, Masamichi
Odagiri, Hayato
Unno, Michiaki
Taki, Yasuyuki
author_facet Tatewaki, Yasuko
Terao, Chiaki Maeda
Ariake, Kyohei
Saito, Ryoko
Mutoh, Tatsushi
Shimomura, Hideo
Motoi, Fuyuhiko
Mizuma, Masamichi
Odagiri, Hayato
Unno, Michiaki
Taki, Yasuyuki
author_sort Tatewaki, Yasuko
collection PubMed
description OBJECTIVES: Metabolic tumor volume (MTV) on (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) is a promising prognostic predictor in pancreatic ductal adenocarcinoma (PDAC). However, the optimal segmentation method and threshold value to determine MTV for PDAC are still unclear. We explored the optimal method and threshold value for the prognostic value of MTV measured on pre-treatment (18)F-FDG-PET/CT. METHODS: Seventy-three patients with resected PDAC who underwent (18)F FDG-PET/CT before surgical resection were enrolled. MTV values of the tumor were measured on FDG-PET/CT by the two fixed-threshold methods using threshold values as 2.0, 2.5, 3.0, and 3.5 for the absolute method and 35%, 40%, 42%, 45%, and 50% for the relative method. Receiver operating characteristic curve analysis for prediction of 1-year survival rates was conducted for determining the optimal threshold values, and we selected the optimal method and threshold value considering area under the curve. The prognostic values of each FDG-PET/CT parameter for disease-specific survival and recurrence-free survival were assessed with Kaplan–Meier method and Cox proportional hazard models. RESULTS: In receiver operating characteristic curve analysis, MTV by the fixed-absolute threshold method based on a threshold value of 3.5 (MTV3.5) performed best in our study with area under the curve 0.724, sensitivity of 65%, and specificity of 75%. In univariate and multivariate analyses, MTV3.5 was significantly associated with disease-specific and recurrence-free survival. CONCLUSIONS: MTV3.5 by absolute threshold on pre-treatment FDG-PET/CT was the best independent prognostic predictor in resectable PDAC compared with other absolute threshold values and relative threshold values.
format Online
Article
Text
id pubmed-7994512
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79945122021-03-27 Defining the Optimal Method for Measuring Metabolic Tumor Volume on Preoperative (18)F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography as a Prognostic Predictor in Patients With Pancreatic Ductal Adenocarcinoma Tatewaki, Yasuko Terao, Chiaki Maeda Ariake, Kyohei Saito, Ryoko Mutoh, Tatsushi Shimomura, Hideo Motoi, Fuyuhiko Mizuma, Masamichi Odagiri, Hayato Unno, Michiaki Taki, Yasuyuki Front Oncol Oncology OBJECTIVES: Metabolic tumor volume (MTV) on (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) is a promising prognostic predictor in pancreatic ductal adenocarcinoma (PDAC). However, the optimal segmentation method and threshold value to determine MTV for PDAC are still unclear. We explored the optimal method and threshold value for the prognostic value of MTV measured on pre-treatment (18)F-FDG-PET/CT. METHODS: Seventy-three patients with resected PDAC who underwent (18)F FDG-PET/CT before surgical resection were enrolled. MTV values of the tumor were measured on FDG-PET/CT by the two fixed-threshold methods using threshold values as 2.0, 2.5, 3.0, and 3.5 for the absolute method and 35%, 40%, 42%, 45%, and 50% for the relative method. Receiver operating characteristic curve analysis for prediction of 1-year survival rates was conducted for determining the optimal threshold values, and we selected the optimal method and threshold value considering area under the curve. The prognostic values of each FDG-PET/CT parameter for disease-specific survival and recurrence-free survival were assessed with Kaplan–Meier method and Cox proportional hazard models. RESULTS: In receiver operating characteristic curve analysis, MTV by the fixed-absolute threshold method based on a threshold value of 3.5 (MTV3.5) performed best in our study with area under the curve 0.724, sensitivity of 65%, and specificity of 75%. In univariate and multivariate analyses, MTV3.5 was significantly associated with disease-specific and recurrence-free survival. CONCLUSIONS: MTV3.5 by absolute threshold on pre-treatment FDG-PET/CT was the best independent prognostic predictor in resectable PDAC compared with other absolute threshold values and relative threshold values. Frontiers Media S.A. 2021-03-12 /pmc/articles/PMC7994512/ /pubmed/33777807 http://dx.doi.org/10.3389/fonc.2021.646141 Text en Copyright © 2021 Tatewaki, Terao, Ariake, Saito, Mutoh, Shimomura, Motoi, Mizuma, Odagiri, Unno and Taki http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Tatewaki, Yasuko
Terao, Chiaki Maeda
Ariake, Kyohei
Saito, Ryoko
Mutoh, Tatsushi
Shimomura, Hideo
Motoi, Fuyuhiko
Mizuma, Masamichi
Odagiri, Hayato
Unno, Michiaki
Taki, Yasuyuki
Defining the Optimal Method for Measuring Metabolic Tumor Volume on Preoperative (18)F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography as a Prognostic Predictor in Patients With Pancreatic Ductal Adenocarcinoma
title Defining the Optimal Method for Measuring Metabolic Tumor Volume on Preoperative (18)F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography as a Prognostic Predictor in Patients With Pancreatic Ductal Adenocarcinoma
title_full Defining the Optimal Method for Measuring Metabolic Tumor Volume on Preoperative (18)F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography as a Prognostic Predictor in Patients With Pancreatic Ductal Adenocarcinoma
title_fullStr Defining the Optimal Method for Measuring Metabolic Tumor Volume on Preoperative (18)F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography as a Prognostic Predictor in Patients With Pancreatic Ductal Adenocarcinoma
title_full_unstemmed Defining the Optimal Method for Measuring Metabolic Tumor Volume on Preoperative (18)F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography as a Prognostic Predictor in Patients With Pancreatic Ductal Adenocarcinoma
title_short Defining the Optimal Method for Measuring Metabolic Tumor Volume on Preoperative (18)F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography as a Prognostic Predictor in Patients With Pancreatic Ductal Adenocarcinoma
title_sort defining the optimal method for measuring metabolic tumor volume on preoperative (18)f-fluorodeoxyglucose-positron emission tomography/computed tomography as a prognostic predictor in patients with pancreatic ductal adenocarcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994512/
https://www.ncbi.nlm.nih.gov/pubmed/33777807
http://dx.doi.org/10.3389/fonc.2021.646141
work_keys_str_mv AT tatewakiyasuko definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma
AT teraochiakimaeda definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma
AT ariakekyohei definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma
AT saitoryoko definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma
AT mutohtatsushi definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma
AT shimomurahideo definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma
AT motoifuyuhiko definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma
AT mizumamasamichi definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma
AT odagirihayato definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma
AT unnomichiaki definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma
AT takiyasuyuki definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma